Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Equity shares.09-04-2024
09-04-2024
Eris Lifesciences Ltd - 540596 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 201806-04-2024
Eris Lifesciences Ltd - 540596 - UPDATE ON ACQUISITION OF THE BRANDED FORMULATIONS BUSINESSES OF BIOCON BIOLOGICS LIMITED
Update on acquisition of the Branded Formulations Businesses of Biocon Biologics Limited02-04-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING28-03-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
TRANSCRIPT OF ANALYST AND INVESTOR CALL21-03-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING18-03-2024
Neutral Eris Lifesciences; target of Rs 930: Motilal Oswal
Motilal Oswal recommended Neutral rating on Eris Lifesciences with a target price of Rs 930 in its research report dated March 14, 2024.18-03-2024
Biocon stock falls 4% after subsidiary sells branded formulations biz to Eris Lifesciences
Biocon Biologics said that it has entered into a long-term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India.15-03-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
RECORDING OF THE CONFERENCE CALL14-03-2024